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Abstract
Objective: To evaluate the accuracy of clinical examination in
determining the stage of operable cervical cancer and the extent of
the disease.
Method: The study involved 58 subjects from outpatient, emer-
gency unit, and ward of Department of Obstetrics and Gynecology
Dr. Cipto Mangunkusumo Hospital, from January 2008 to Decem-
ber 2010 with a diagnosis of cervical cancer. Patients who were di-
agnosed with cervical cancer up to stage IIA were included and pa-
tients lost to follow-up, receiving preoperative neo-adjuvant che-
motherapy, and died before getting treatment were excluded. The
outcomes evaluation were postoperative clinical staging, including
the presence of enlarged lymph nodes, parametrial involvement, and
tumor size. Lymph nodes, parametrial, and the tumor size were as-
sessed from the surgery and pathological anatomy results.
Result: The age distribution of 58 subjects ranged from 25 to 70
years (mean 48.39 years, SD 8.82). Squamous cell carcinoma was
the most frequent type (44.9%), followed by adenocarcinoma
(24.1%). Errors in preoperative clinical staging compared with post-
operative was 40% in stage IA1, 9.52% in stage IB1, 17.65% in
stage IB2, and 7.14% in stage IIA. Sensitivity, specificity, positive
predictive value, and negative predictive value for preoperative
clinical examination of lymph nodes were 11.1%, 100%, 100%, and
85.96%. Sensitivity, specificity, positive predictive value, and ne-
gative predictive value for preoperative clinical examination of pa-
rametrial involvement were 37.5%, 100%, 100%, and 90.90%. Sen-
sitivity, specificity, positive predictive value, and negative predic-
tive value for preoperative clinical examination of the tumor size
were 91.84%, 88.89%, 97.83% and 66.67%.
Conclusion: Clinical examination has limitation, especially in
determining lymph nodes and parametrial involvement. Other diag-
nostic modalities in determining the extent of the disease is ne-
cessary. Enforcement of the right diagnosis in patients with cervi-
cal cancer is needed to determine the appropriate treatment.
[Indones J Obstet Gynecol 2011; 35-1: 25-9]
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Abstrak
Tujuan: Untuk mengevaluasi ketepatan pemeriksaan klinis da-
lam menentukan staging kanker serviks yang operable dan penye-
barannya.
Metode: Penelitian melibatkan 58 subjek pasien poliklinik, Ins-
talasi Gawat Darurat dan Public Wing Obstetri dan Ginekologi
RSUPN Dr. Cipto Mangunkusumo, Jakarta, sejak Januari 2008
sampai Desember 2010 dengan diagnosis kanker serviks. Kriteria
inklusi adalah pasien poliklinik, Instalasi Gawat Darurat dan Pu-
blic Wing Obstetri dan Ginekologi RSUPNCM yang didiagnosis
kanker serviks secara klinis mencapai staging IIA. Kriteria eksklusi
adalah pasien kanker serviks yang lost to follow up, mendapatkan
neo adjuvant chemotherapy preoperatif, dan meninggal sebelum
mendapatkan terapi. Luaran yang diteliti adalah staging klinis
pascaoperatif termasuk pembesaran kelenjar getah bening, keter-
libatan parametrium dan ukuran tumor. Kelenjar getah bening,
parametrium dan ukuran serviks dinilai dari hasil operasi dan
patologi anatomi.
Hasil: Dari 58 subjek penelitian ini, didapatkan rentang usia
dari 25 sampai dengan 70 tahun dengan rerata usia 48,39 thn (SD
8,82). Karsinoma sel skuamosa merupakan tipe histopatologi ter-
banyak (44,9%) dan diikuti oleh adenokarsinoma dengan 24,1%.
Kesalahan staging secara klinis preoperatif dibandingkan dengan
pascaoperatif didapatkan pada stadium IA1 sebesar 40%, IB1 sebe-
sar 9,52%, IB2 sebesar 17,65% dan IIA sebesar 7,14%. Sensitivitas,
spesifisitas, nilai duga positif, dan nilai duga negatif dari pemerik-
saan klinis kelenjar getah bening preoperatif adalah 11,1%, 100%,
100%, dan 85,96%. Sensitivitas, spesifisitas, nilai duga positif, dan
nilai duga negatif dari pemeriksaan klinis parametrium preoperatif
adalah 37,5%, 100%, 100%, dan 90,90%. Sensitivitas, spesifisitas,
nilai duga positif, dan nilai duga negatif untuk pemeriksaan klinis
ukuran serviks preoperatif adalah 91,84%, 88,89%, 97,83% dan
66,67%.
Kesimpulan: Pemeriksaan secara klinis memiliki keterbatasan
terutama dalam menentukan keterlibatan KGB dan parametrium.
Diperlukan modalitas diagnosik tambahan dalam menentukan ke-
terlibatannya. Penegakan diagnosis yang tepat pada pasien dengan
kanker serviks diperlukan untuk menentukan perencanaan terapi
yang tepat.
[Maj Obstet Ginekol Indones 2011; 35-1: 25-9]
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INTRODUCTION
Cervical cancer is a malignant disease with mortality
and morbidity rate higher than 280,000 and 500,000
women respectively each year worldwide. This fact
puts cervical cancer as the second largest cancer in
the world and ranked first in developing countries in-
cluding Indonesia.1-4 80% of these cases occur in de-
veloping countries where more than two-thirds of the
cases are found in an advanced stage that cause low
survival rates. Asia has nearly 1390,4 million women
aged 15 years or more, at risk to develop cervical
cancer each year. It is estimated there are 265,884
women who are diagnosed with cervical cancer and
142,735 died because of it each year.5 In Indonesia,
it is estimated there are 15,050 women who are diag-
nosed with cervical cancer and 7,566 die of it annu-
ally. According to WHO data in 2004, 40% cases of
cervical cancer in the world found in Southeast Asia.6
Cervical cancer is atypical in nature and does not
have certain symptoms and signs in early develop-
ment, thus requiring every woman to continue to
make early diagnosis by cytological examination of
Papanicolaou tests (Pap). Pap tests have been done
routinely in developed countries and give good results
in decreasing the incidence of cervical cancer by 50
- 60%.7-9 Routine examination are difficult in devel-
oping countries like Indonesia because of difficulties
in access to the service center that has a laboratory
and professional health personnel, the price of Pap
tests that are relatively expensive and the need for
repeated visits to the health center.9-11 These difficul-
ties make lots of women in Indonesia reluctant to do
the screening. Whereas routine screening of early sta-
ge cervical cancer are more easily diagnosed and with
proper management will reduce the incidence of cer-
vical cancer.10,11
The high incidence of cervical cancer in develop-
ing countries is due to a lack of effective programs
that can do the screening and immediate treatment of
pre-cancerous lesions adequately before the lesions
develop into invasive cancer. Like in Indonesia, the
existing screening programs using Pap tests are often
ineffective, it is because Indonesia’s population are
more than 237.56 million people, with geographical
factors that consists of 17,000 islands is not balanced
when compared to the availability of facilities and
human resources necessary to perform screening.12
Based on data obtained from the Indonesia Patholo-
gist Society13, the number of anatomical pathologist
until the year 2009 throughout Indonesia is 297 peo-
ple and the number of its cytotechnician is only
amounted to less than 100 people. While according
to the Indonesia Obstetrician and Gynecologist Asso-
ciation (POGI) the number of obstetrics and gyneco-
logy specialists is currently about 2350 people.14 This
imbalance is causing the low screening coverage in
Indonesia.
To diagnose advanced stage of cervical cancer is
not difficult. The problem is how to diagnose cervical
cancer in early stage with highest accuracy as possi-
ble.8,15-17 A multi-institutional study by the Gyneco-
logic Oncology Group (GOG) has confirmed that cli-
nical staging is often inaccurate in determining the
extent of disease in patients with cervical cancer.18
Clinical staging is inaccurate in 50% of the patients.
Most of patients will experience "upstaging" at the
time of surgical exploration, usually due to a hidden
node metastasis.19 The greatest difficulties in the cli-
nical evaluation of patients with cervical cancer are
the assessment of parametrial and pelvic sidewall in-
vasion, beside the evaluation of lymph node and dis-
tant metastasis.20
Condition of the lymph node is one of the key to
determine the prognosis and treatment of cervical can-
cer. However, because it is not possible to detect
clinically pelvic and para-aortic lymph node metasta-
sis, surgery such as lymphadenectomy may reveal me-
tastatic spread. Lately, the use of magnetic resonance
imaging (MRI) and computed tomography (CT) to de-
termine the status of the lymph nodes also have been
increased, but not one of these methods incorporated
into the FIGO staging of cervical cancer. Sentinel
node biopsy and positron emission tomography (PET)
also has started being used.21
Invasion of the parametrial is also an important
factor in the pre-operative evaluation of cervical can-
cer that significantly influences staging and treat-
ment.22 It is important to determine whether the tumor
extends into the parametrial. The degree of parame-
trial tumor extension has been assessed mainly by
clinical examination. Clinical staging, however, is of-
ten inaccurate. A discrepancy of 34 - 39% has been
reported between clinical and surgical staging.23
Clinical staging is limited, surgical staging, even
though invasive, has significant benefit in identify pa-
tients with metastasis. Identification in these patients
will determine the most accurate therapy.24
METHODS
This retrospective study was conducted on 58 cervical
cancer patients in Dr. Cipto Mangunkusumo General
Hospital, Jakarta, Indonesia from January 2008 until
December 2010. The study involved 58 subjects from
outpatient, emergency unit, and ward of Obstetrics
and Gynecology Dr. Cipto Mangunkusumo Hospital,
from January 2008 to December 2010 with a diagno-
sis of cervical cancer. Patients who were diagnosed
with cervical cancer up to stage IIA were included
and patients lost to follow-up, receiving preoperative
neo-adjuvant chemotherapy, and died before getting
treatment were excluded.
Cervical cancer staging is determined by clinical
examination and grouped based on the International
Federation of Gynecologic and Obstetrics (FIGO) cer-
vical cancer staging. Parametrial and lymph nodes
status are also examined in clinical examination sta-
ging.
The outcomes evaluated were postoperative clini-
cal staging, including the presence of enlarged lymph
nodes, parametrial involvement, and tumor size. Lym-
ph nodes, parametrial, and the tumor size were as-
sessed from the surgery and pathological anatomy re-
sults. The research data is processed using SPSS soft-
ware 16.00. The statistical analysis used in this study
is descriptive analysis and diagnostic comparative
between clinical examination staging, lymph nodes
and parametrial condition pre and postoperatively.
Indones J
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RESULT
In this study, there were 58 subjects with age varied
25 - 70 years with a mean age of 48.39 years (SD
8.82) who were diagnosed with cervical cancer and
fulfilled inclusion criteria. Of the 58 study subjects,
majority was diagnosed with stage IB1 (36.2%) both
by clinical staging and postoperatively (36.2%).
Whereas in clinical staging stage IB2 and IIA had
29.3% each and both was a second rank; in surgical
staging, stage IB2 and IIA were a second and third
rank with 29.3% and 24.1%, respectively.
Errors on cervical cancer staging were seen in all
stages. Error rate are 40%, 9.52%, 17.65% and 7.14%
consecutively to diagnose stage IA1, IB1, IB2 and
IIA. (Table 1)
Based on the histopathology results, the majority
of cervical cancer are keratinized squamous cell car-
cinoma and adenocarcinoma 25.9 and 24.1%, respec-
tively. Unkeratinized squamous cell carcinoma (19%)
and Adenosquamosa carcinoma (13.8%) also held a
big number. Other types like endometrioid adenocar-
cinoma, clear cell carcinoma and small cell carcinoma
are also found in small numbers.
Lymph nodes that being assessed are pelvic lymph
nodes based on clinical examination. Based on exami-
nation, there is only 1 patient that has lymph nodes
involvement. Sensitivity, specificity, positive predic-
tive value and negative predictive value for lymph
nodes examination are 11.11%, 100%, 100% and
85.96%. (Table 2)








positive 1  0  1
negative 8 49 57
Total 9 49 62
Parametrial are the connective tissue of the pelvic
wall that extend laterally from the anterior fornix and
between the broad ligament layers sensitivity, speci-
ficity, positive predictive value and negative predic-
tive value for parametrial involvement are 37.5%,
100%, 100% and 90.90%. (Table 3)







positive 3  0  3
negative 5 50 55
Total 8 50 58
Cervical length were also compared and grouped
into 2 categories which are less and more than 4 cm.
Sensitivity, specificity, positive predictive value and
negative predictive value for cervical length exami-
nation are 91.84%, 88.89%, 97.83% and 66.67%.
(Table 4)














 4 8 12
Total 49 9 58
DISCUSSION
Staging of cervical cancer is a clinical staging, using
staging system from FIGO, that is also approved by
American Joint Committee on Cancer (AJCC). The
use of MRI, CT-scan, and PET-CT can help to deter-
mine the most appropriate therapy, but are not used
to determine the staging of cervical cancer.25
Table 1. The preoperative and post operative clinical staging.
Post-operative diagnosis
Total
Stad IA1 Stad IB1 Stad IB2 Stad IIA Stad IIB
Pre-operative
Diagnosis
Stad IA1 3  0  0  0 0  3
Stad IB1 2 19  0  0 0 21
Stad IB2 0  2 14  1 0 17
Stad IIA 0  0  3 13 1 17
Total 5 21 17 14 1 58
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From 58 patients in our study, we found a normal
distribution of age with mean 48.39 years old. This
is consistent with the literature that mention the in-
creased incidence of cervical cancer in the age range
from 25 - 34 years old and showed a peak at age 35
- 44 years old in Dr. Cipto Mangunkusumo General
Hospital and 45 - 54 years old in Indonesia.26,27
From histopatology results, it is showed that the
majority type are squamous cell carcinoma with kera-
tin and adenocarcinoma, respectively 25.9 and 24.1%.
Based on the literature, 70 - 80% of cervical cancer
are squamous cell carcinomas type with 90% of early
lesions originated from the transformation zone
squamo-columnar junction of cervical epithelial cells.
Changes from normal cells to dysplastic cells can last
for 7 - 10 years.28 Squamous cell carcinoma without
keratin accounted for 19%, so that makes the percent-
age of all squamous cell carcinoma was 44.9%.
Cervical cancer staging is still performed clini-
cally; therefore, there should not be any mistakes in
determining the stage of cervical cancer. In our study,
each stage has a different percentage of error. The
error obtained in making the diagnosis in stage IA1
was 40%, IB1 was 9.52%, IB2 was 17.65%, and IIA
was 7.14%. In stage IB1, errors of diagnosis were
found with 2 of 21 patients diagnosed with IB1,
turned out to be at stage IA1 in surgical staging. In
stage IB2, errors of diagnosis were found with down-
staging of 2 patients who are supposedly in stage IB1
and upstaging with 1 patient who are supposedly in
stage IIA in surgical staging out of 17 patients who
are diagnosed as satge IB2. In stage IIA, errors of
diagnosis were found with downstaging of 3 patients
who are supposedly in stage IB2 and upstaging with
1 patient who are supposedly in stage IIB in surgical
staging out of 17 patients who are diagnosed as stage
IIA. Of 17 patients with clinical diagnose of stage
IB2, there were 2 cases that undergo downstaging to
IB1 and 1 case went upstage to IIA. Of 17 patients
with clinical diagnose of stage IIA, 3 cases were
found to be at stage IB2 in surgical staging and 1
case were found to be at stage IIB in surgical staging.
The biggest error in making the clinical staging in
our study was found at stage IA1 with 2 of 5 cases
that are supposedly IA1 are diagnosed as a stage IA2.
This unseemingly big error may be caused by some
reasons. A few numbers of cases in our study, diffe-
rent skills of the clinician who staged clinically and
operatively could be the causes of the big errors.
The therapy for cervical cancer in stage IB and IIA
is hysterectomy radical with pelvic lymphadenecto-
my, therefore, the mistake in staging between them
can still be "accepted". But, there were differences in
error in diagnosing patients between staging IIA and
IIB. At stage IIB, the therapy is radiotherapy {exter-
nal radiation, continued by intracavitary radiotherapy
(high dose rate or low dose rate)} and chemoradia-
tion. Radiotherapy can be given to primary treatment,
preoperative adjuvant, and palliative.
Lymph node metastasis are a risk factor that influ-
ences the prognosis. Sentinel lymph node can be used
to detect the lymph nodes with sensitivity 83.3%,
positive predictive value 97.1%, and negative predic-
tive value 16.6%.17,29-31 Our study showed that clini-
cal examination of lymph nodes has sensitivity
11.11%, specificity 100%, positive predictive value
100%, and negative predictive value 85.96%.
Parametrial involvement was examined clinically
and confirmed by pathology anatomy examination.
Clinical examination of parametrial involvement has
sensitivity of 37.5%, specificity of 100%, positive
predictive value of 100%, and negative predictive
value of 90.90%. 
The tumor size can be classified into bulky (> 4cm)
and non-bulky (≤ 4cm) tumor. The tumor size was
examined clinically and confirmed by surgical stag-
ing. The sensitivity, specificity, positive predictive va-
lue, and negative predictive value for clinical exami-
nation of tumor size were 91.84%, 88.89%, 97.83%
and 66.67%.
Further analysis will be done toward this research
to take into account the time between diagnosing and
treating the cervical cancer, as it has not been ac-
counted before.
CONCLUSION
The error rate are 40%, 9.52%, 17.65% and 7.14%
consecutively to diagnose stage IA1, IB1, IB2 and
IIA. Sensitivity, specificity, positive predictive value
and negative predictive value for lymph nodes exami-
nation are 11.11%, 100%, 100% and 85.96%. Sensi-
tivity, specificity, positive predictive value and nega-
tive predictive value for parametrial involvement are
37.5%, 100%, 100% and 90.90%. Sensitivity, speci-
ficity, positive predictive value and negative predic-
tive value for cervical length examination are 91.84%,
88.89%, 97.83% and 66.67%. Supportive examina-
tions would help clinician to obtain an optimal result
of staging.
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